Speakers
Michael Fossel
President & Founder
Telocyte
Day One
Wednesday, August 25 2021
10:25 am | Chair Led Q&A
10:05 am | Challenging Differentiated Approach to Neurodegeneration: A Unified Systems Model for Age-Related Neurodegenerative Disease
Andreas Jeromin
Chief Scientific Officer
Cohen Veterans Bioscience
Day One
Wednesday, August 25 2021
3:40 pm | Blood-based biomarkers in AD : When the Future Becomes the Present
Chris Whelan
Associate Director & Head of Translational Genetics
Biogen
Day One
Wednesday, August 25 2021
12:40 pm | Chair Led Q&A
11:40 am | Dementia, Biomarkers and Biobanks: Applying Proteomics at Population Scale
Leslie Holsinger
Executive Vice President of Research & Development
Cortexyme
Day One
Wednesday, August 25 2021
12:40 pm | Chair Led Q&A
12:00 pm | Use of Novel Biomarkers of P. Gingivalis Infection & Neuroinflammation in the GAIN Trial; An Ongoing Phase 2/3 Clinical Trial Assessing the Activity of Atuzaginstat in Patients with Mild to Moderate Alzheimer’s Disease
Michela Gallagher
Founder & Chief Executive Officer
AgeneBio
Day One
Wednesday, August 25 2021
10:25 am | Chair Led Q&A
9:30 am | Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The HOPE4MCI Trial
Sharon Rosenzweig-Lipson
Vice President of Research & Development
AgeneBio
Day One
Wednesday, August 25 2021
10:25 am | Chair Led Q&A
9:30 am | Integrating Biomarkers into Trial Design, Patient Selection & Outcome Measures: AgeneBio’s The HOPE4MCI Trial
CJ Barnum
Head of Neuroscience
INmune Bio
Day Two
Thursday, August 26 2021
12:00 pm | Chair Led Q&A; Precision Through Combination Biomarkers
11:20 am | What it Means to Demonstrate Target Engagement in Therapies that Target the Immune System: Role of Combination of Biomarkers.
10:20 am | Chair Led Q&A; Presenting Biomarker Efficacy & Advances in Clinical Validation of Biomarker’s for Alzheimer’s Disease
9:00 am | Biomarkers to Evaluate Therapies that Target the Immune System in Early-Stage Alzheimer’s Trials: Patient Selection, Target Engagement, & Promising Technologies
Hans Moebius
Chief Medical Officer
Athira Pharma
Day One
Wednesday, August 25 2021
3:00 pm | Chair Led Q&A
2:40 pm | Advances in Direct, Functional, Non-Invasive Biomarkers; Athira’s Utilization of ERP P300
Juli Jones
Director & Head of Disease Biology
Cyclerion Therapeutics
Chrisopher Winrow
Head of Translational Medicine
Cyclerion Therapeutics
Day Two
Thursday, August 26 2021
1:40 pm | Chair Led Q&A; Translating Biomarkers from Preclinical to Clinical Development
1:20 pm | Leading the Vanguard - Early Clinical Assessment of Biomarkers to Drive Development of Alzheimer’s Disease Therapies
Michele Vendruscolo
Chief Scientific Officer
Wren Therapeutics
Day One
Wednesday, August 25 2021
3:00 pm | Chair Led Q&A
2:20 pm | Detection & Quantification of Amyloid Beta Oligomers
Jonathan Levenson
Vice President of Translational Biology
Tiaki Therapeutics
Day One
Wednesday, August 25 2021
3:00 pm | Chair Led Q&A
2:00 pm | Using Multi-Omics Data to Identify Novel Biomarkers & Biomarker Strategies
Stan Chamberlain
Chief Scientific Officer
T3D Therapeutics
Day One
Wednesday, August 25 2021
4:05 pm | Panel Discussion: Advances in Identifying Novel Non-Invasive Biomarkers to Identify Patients with Alzheimer’s Disease, Their Specific Subtype & Disease Progression
Felix Yeh
Head of Biomarkers
Alector
Day One
Wednesday, August 25 2021
12:40 pm | Chair Led Q&A
12:20 pm | Biomarker Strategies to Enable Successful Development of Immuno-Neurology Targets
Mark Frasier
Co-Chief Scientific Officer
The Michael J Fox Foundation
Day One
Wednesday, August 25 2021
4:05 pm | Panel Discussion: Advances in Identifying Novel Non-Invasive Biomarkers to Identify Patients with Alzheimer’s Disease, Their Specific Subtype & Disease Progression
Nicole Bjorklund
Assistant Director – Scientific Affairs
Alzheimer’s Drug Discover Foundation
Day Two
Thursday, August 26 2021
12:00 pm | Chair Led Q&A; Precision Through Combination Biomarkers
11:40 am | Emerging Biomarker Combinations for Personalized Alzheimer’s Disease Diagnosis & Treatment
Ralph Kern
President & Chief Medical Officer
BrainStorm Cell Therapeutics
Day One
Wednesday, August 25 2021
10:25 am | Chair Led Q&A
9:00 am | Opening Presentation: Treating Alzheimer’s Disease as a Heterogenous Disease
Stacy Lindborg
Executive Vice President & Head of Global Clinical Research
BrainStorm Cell Therapeutics
Day One
Wednesday, August 25 2021
10:25 am | Chair Led Q&A
9:00 am | Opening Presentation: Treating Alzheimer’s Disease as a Heterogenous Disease
Douglas Galasko
Associate Director
UCSD Shiley-Marcos Alzheimer’s Disease Research Center
Day Two
Thursday, August 26 2021
10:20 am | Chair Led Q&A; Presenting Biomarker Efficacy & Advances in Clinical Validation of Biomarker’s for Alzheimer’s Disease
9:40 am | Presenter Led Audience Discussion
9:20 am | Mapping Alzheimer Biomarkers for Context of Use With the FDA BEST (Biomarkers, Endpoints, and other Tools) Guidance
Elizabeth Somers
Director of Diagnostic Development & Translational Medicine Diagnostic Development, Translational Medicine & Diagnostics
Eisai
Maria Maccecchini
Founder, President, CEO and Executive Board Member
Annovis Bio
Day Two
Thursday, August 26 2021